

LEONABIO, INC.

DISCLOSURE COMMITTEE CHARTER

(As amended and restated on January 9, 2026)

This Disclosure Committee (the “**Committee**”) of LeonaBio, Inc. (the “**Company**”) shall be appointed by the Chief Executive Officer and Chief Financial Officer of the Company (the “**Senior Officers**”) to perform the duties and responsibilities set forth in this charter.

A. PURPOSE

The purpose of the Committee shall be to (i) assist in the Company’s efforts to maintain effective disclosure controls and procedures and to ensure that the information required to be disclosed by the Company in the reports it files or submits to the Securities and Exchange Commission (“**SEC**”) and other information that the Company publicly discloses is, in all material respects, recorded, processed, summarized and reported accurately to senior management of the Company, including the Senior Officers, as appropriate to allow timely decisions regarding and the accuracy of such disclosure, and (ii) to review with management its ongoing compliance with these protocols and procedures as necessary to conform to best practices.

B. COMPOSITION

The Company’s Chief Financial Officer shall be the chairperson of the Committee and shall be responsible for setting the agenda of the Committee at its meetings (or at any meeting of a subgroup of the Committee), coordinating the activities of the Committee, and implementing the information gathering processes in accordance with the requirements of this Charter within the various business units or departments of the Company.

In addition to the Company’s Chief Financial Officer, the Committee shall include the Company’s Chief Operating Officer, General Counsel and Chief Compliance Officer, Chief Medical Officer, Chief Scientific Officer and such personnel of the Company as determined by the Senior Officers in their discretion, which personnel may be drawn from various areas of the Company, including the following functions: financial planning & analysis, operations, risk management, internal audit (if any), investor relations, human resources, information security, research and development, regulatory compliance, clinical operations and such other individuals as the Senior Officers deem suitable based on their substantive area(s) of responsibility and potential contribution to the Disclosure Committee. Representatives of the Company’s outside legal counsel, independent auditors and other personnel of the Company or representatives of its outside advisors may be invited to attend meetings of the Committee, as the Committee deems necessary or appropriate in performing its functions.

Changes to the membership of the Committee shall be determined by the chairperson and approved by the Senior Officers as necessary in light of changes in the Company’s business, operations, organization or management.

C. RESPONSIBILITIES

The Committee reports to the Senior Officers, with decision-making authority regarding the Company's disclosure controls and procedures as well as the Company's external disclosures. The following are the principal recurring responsibilities of the Committee.

1. Design, adopt and implement appropriate procedures and policies, and monitor such procedures and policies, to ensure the material accuracy and timely collection of information for inclusion in the Company's periodic and current SEC reports, the Company's quarterly earnings press releases, and other public disclosures (the "**Disclosure Controls Policies and Procedures**").

2. Evaluate the effectiveness of the Disclosure Controls Policies and Procedures on at least an annual basis and amend the same as necessary to conform to best practices.

3. Establish and review timelines relating to the preparation and filing of the Company's quarterly earnings press releases and periodic SEC reports.

4. Establish as appropriate policies and procedures to ensure relevant Company personnel timely report to the Committee information potentially requiring disclosure.

5. Establish responsibility and lines of communication throughout the Company's operations and business units for collecting relevant information on a timely basis, including making periodic inquiries with relevant Company personnel possessing information potentially requiring disclosure.

6. Review drafts of quarterly earnings press releases and related materials (such as scripts for conference calls with financial analysts and investors) and periodic SEC reports in preparation for filing, including final drafts. In connection with this review, the Disclosure Committee shall timely discuss any material disclosure deficiencies noted concerning the Company's drug research, lead drug candidates, development, manufacturing, and operations in order to determine whether additional disclosure is warranted.

7. Meet periodically during the preparation of quarterly earnings press releases and periodic SEC reports to discuss disclosure matters and filings made by the Company to ensure the material completeness and accuracy of content.

8. Coordinate, as necessary, the review of quarterly earnings press releases and related materials and periodic and current SEC reports with the Senior Officers, the Company's independent accountants, internal auditors (if any), outside counsel and the Audit Committee of the Board of Directors.

9. Periodically report to the Chief Financial Officer, the Chairperson of the Audit Committee of the Board of Directors, and the Chairperson of the Compliance Committee of the Board of Directors in connection with the preparation and filing of quarterly earnings press releases on Form 8-K, quarterly SEC reports on Form 10-Q, and annual SEC reports on Form 10-K on disclosure issues and the Committee's findings regarding the effectiveness of its procedures and policies, including any material weaknesses identified therein or in the Company's Disclosure Controls Policies and Procedures generally.

10. Consult with the Company's Chief Medical Officer and Chief Scientific Officer, as necessary, with respect to disclosures related to their areas of responsibility, including, but not limited to: (i) the Company's research and development activities; (ii) clinical trials, clinical trial results, and/or studies; and (iii) compliance with relevant laws, rules and regulations relating thereto.

11. Review investor presentations and transcripts of publicly available conference calls with financial analysts for the material accuracy of any disclosures made, advise the Audit Committee of any corrections that legally need to be made, and draft any required corrective disclosures.

12. Evaluate the materiality of corporate information and events relating to or affecting the Company and determine the timing and appropriate method of disclosure of corporate information deemed material.

13. Undertake any other duties or responsibilities as the Senior Officers may from time to time prescribe.

14. Institute pre-clearing mechanisms for any material corporate information disseminated on social media and other non-SEC platforms delivering corporate information to investors.

D. GENERAL

1. It is anticipated that the Committee will hold regular meetings as directed by the Senior Officers or as the Committee otherwise deems appropriate, but in no event shall the Committee meet less than four times per calendar year.

2. This Charter shall be reviewed periodically by the members of the Committee. Any changes to the Charter must be approved by the Senior Officers.